Verastem IncNASDAQ:VSTM
- LAST PRICE12.1800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots16.1500/ 2
- Ask / Lots16.4000/ 3
- Open / Previous Close0.0000 / 12.1800
- Day Range---
- 52 Week Range
- Volume53,548
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VSTM |
|---|---|---|
| 09:32 ET | 1936 | 11.86 |
| 09:41 ET | 100 | 12.09 |
| 09:50 ET | 600 | 11.82 |
| 09:54 ET | 475 | 11.75 |
| 09:57 ET | 400 | 11.81 |
| 09:59 ET | 100 | 11.89 |
| 10:06 ET | 100 | 11.9 |
| 10:10 ET | 100 | 11.9 |
| 10:14 ET | 1200 | 11.91 |
| 10:17 ET | 100 | 11.97 |
| 10:19 ET | 202 | 11.98 |
| 10:21 ET | 100 | 12.05 |
| 10:26 ET | 1322 | 11.91 |
| 10:30 ET | 100 | 11.89 |
| 10:33 ET | 600 | 11.8 |
| 10:35 ET | 100 | 11.785 |
| 10:44 ET | 100 | 11.75 |
| 10:46 ET | 600 | 11.79 |
| 10:53 ET | 300 | 11.77 |
| 11:06 ET | 300 | 11.8299 |
| 11:08 ET | 200 | 11.87 |
| 11:11 ET | 100 | 11.94 |
| 11:13 ET | 100 | 11.865 |
| 11:15 ET | 200 | 11.8101 |
| 11:24 ET | 100 | 11.96 |
| 11:27 ET | 200 | 11.915 |
| 11:31 ET | 100 | 11.87 |
| 11:33 ET | 100 | 11.87 |
| 11:40 ET | 100 | 11.88 |
| 11:45 ET | 500 | 11.94 |
| 11:47 ET | 100 | 11.96 |
| 11:51 ET | 4322 | 11.92 |
| 11:56 ET | 200 | 11.905 |
| 11:58 ET | 100 | 11.905 |
| 12:03 ET | 300 | 11.91 |
| 12:07 ET | 100 | 11.91 |
| 12:12 ET | 100 | 11.91 |
| 12:16 ET | 100 | 11.91 |
| 12:21 ET | 100 | 11.905 |
| 12:23 ET | 100 | 11.905 |
| 12:25 ET | 100 | 11.86 |
| 12:32 ET | 1200 | 11.8 |
| 12:36 ET | 100 | 11.9 |
| 12:38 ET | 210 | 11.8001 |
| 12:41 ET | 100 | 11.82 |
| 12:45 ET | 300 | 11.8 |
| 12:48 ET | 200 | 11.72 |
| 12:50 ET | 324 | 11.69 |
| 12:56 ET | 100 | 11.67 |
| 01:01 ET | 200 | 11.67 |
| 01:12 ET | 100 | 11.6 |
| 01:33 ET | 500 | 11.62 |
| 01:35 ET | 432 | 11.63 |
| 01:37 ET | 950 | 11.645 |
| 01:42 ET | 300 | 11.68 |
| 01:44 ET | 200 | 11.64 |
| 01:48 ET | 200 | 11.65 |
| 01:50 ET | 200 | 11.69 |
| 01:55 ET | 300 | 11.64 |
| 01:57 ET | 100 | 11.61 |
| 02:00 ET | 130 | 11.646 |
| 02:02 ET | 600 | 11.63 |
| 02:08 ET | 600 | 11.58 |
| 02:11 ET | 200 | 11.5 |
| 02:13 ET | 100 | 11.53 |
| 02:15 ET | 600 | 11.5 |
| 02:18 ET | 100 | 11.46 |
| 02:20 ET | 100 | 11.49 |
| 02:22 ET | 900 | 11.47 |
| 02:27 ET | 1200 | 11.48 |
| 02:29 ET | 208 | 11.505 |
| 02:31 ET | 190 | 11.4929 |
| 02:33 ET | 100 | 11.4951 |
| 02:36 ET | 100 | 11.5 |
| 02:44 ET | 1100 | 11.515 |
| 02:49 ET | 1197 | 11.57 |
| 02:54 ET | 800 | 11.605 |
| 02:58 ET | 1300 | 11.59 |
| 03:02 ET | 166 | 11.568 |
| 03:03 ET | 200 | 11.59 |
| 03:05 ET | 3154 | 11.64 |
| 03:07 ET | 583 | 11.67 |
| 03:09 ET | 1100 | 11.665 |
| 03:12 ET | 902 | 11.675 |
| 03:14 ET | 400 | 11.645 |
| 03:18 ET | 400 | 11.69 |
| 03:23 ET | 830 | 11.65 |
| 03:27 ET | 600 | 11.6 |
| 03:30 ET | 800 | 11.63 |
| 03:34 ET | 100 | 11.63 |
| 03:38 ET | 100 | 11.635 |
| 03:39 ET | 100 | 11.65 |
| 03:41 ET | 200 | 11.65 |
| 03:43 ET | 700 | 11.631 |
| 03:45 ET | 700 | 11.64 |
| 03:48 ET | 200 | 11.62 |
| 03:50 ET | 100 | 11.61 |
| 03:52 ET | 4900 | 11.795 |
| 03:54 ET | 3869 | 11.92 |
| 03:56 ET | 6873 | 12.08 |
| 03:57 ET | 10544 | 12.1 |
| 03:59 ET | 8211 | 12.18 |
Today
Yesterday
DJ Verastem Shares Surge 51% After Pancreatic Cancer Treatment Study Data, from 12 hours ago by Dow Jones
12 hours ago by Dow JonesVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer, from 14 hours ago by Dow Jones
14 hours ago by Dow Jones
May 13, 2024
DJ Verastem Price Target Maintained With a $17.50/Share by HC Wainwright & Co., from 7:10AM ET on Monday May 13, 2024 by Dow Jones
7:10AM ET on Monday May 13, 2024 by Dow Jones
May 9, 2024
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates, from 4:02PM ET on Thursday May 09, 2024 by Dow Jones
4:02PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verastem Inc | 308.5M | -2.8x | --- |
Atea Pharmaceuticals Inc | 310.8M | -1.9x | --- |
Ventyx Biosciences Inc | 313.7M | -1.4x | --- |
Alto Neuroscience Inc | 316.2M | -6.2x | --- |
Solid Biosciences Inc | 299.7M | -2.0x | --- |
Candel Therapeutics Inc | 318.0M | -8.3x | --- |
Company Information
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
Contact Information
- Headquarters
- 117 Kendrick Street, Suite 500CAMBRIDGE, MA, United States 02494
- Phone
- 781-292-4200
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Daniel Paterson
- Chief Financial Officer
- Daniel Calkins
- Lead Independent Director
- Michael Kauffman
- Director
- Robert Gagnon
- Director
- Brian Stuglik
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $308.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-4.40 |
Book Value | $3.11 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
